News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
132,012 Results
Type
Article (18208)
Company Profile (40)
Press Release (113760)
Multimedia
Podcasts (36)
Webinars (3)
Section
Business (27813)
Career Advice (2555)
Deals (4533)
Drug Delivery (59)
Drug Development (20867)
Employer Resources (125)
FDA (3009)
Job Trends (3894)
News (57024)
Policy (6314)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1095)
Accelerated approval (16)
Adcomms (17)
Allergies (43)
Alliances (7554)
ALS (72)
Alzheimer's disease (466)
Antibody-drug conjugate (ADC) (159)
Approvals (3094)
Artificial intelligence (279)
Autoimmune disease (114)
Automation (18)
Bankruptcy (51)
Best Places to Work (2939)
BIOSECURE Act (5)
Biosimilars (63)
Biotechnology (27)
Bladder cancer (115)
Brain cancer (33)
Breast cancer (300)
Cancer (2747)
Cardiovascular disease (173)
Career advice (2133)
Career pathing (38)
CAR-T (307)
CDC (24)
Celiac Disease (1)
Cell therapy (640)
Cervical cancer (17)
Clinical research (18020)
Collaboration (816)
Company closure (2)
Compensation (454)
Complete response letters (17)
COVID-19 (1305)
CRISPR (55)
C-suite (359)
Cystic fibrosis (55)
Data (2994)
Decentralized trials (1)
Denatured (6)
Depression (46)
Diabetes (262)
Diagnostics (1187)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (30)
Drug discovery (110)
Drug pricing (93)
Drug shortages (7)
Duchenne muscular dystrophy (86)
Earnings (11092)
Editorial (53)
Employer branding (19)
Employer resources (115)
Events (21464)
Executive appointments (451)
FDA (4271)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (3)
Frontotemporal dementia (8)
Funding (699)
Gene editing (112)
Generative AI (26)
Gene therapy (298)
GLP-1 (382)
Government (1524)
Grass and pollen (5)
Guidances (121)
Healthcare (4469)
HIV (41)
Huntington's disease (21)
IgA nephropathy (20)
Immunology and inflammation (113)
Immuno-oncology (37)
Indications (43)
Infectious disease (1415)
Inflammatory bowel disease (67)
Inflation Reduction Act (7)
Influenza (37)
Intellectual property (72)
Interviews (512)
IPO (2219)
IRA (19)
Job creations (1156)
Job search strategy (1718)
JPM (49)
Kidney cancer (8)
Labor market (61)
Layoffs (232)
Leadership (36)
Legal (1319)
Liver cancer (40)
Longevity (5)
Lung cancer (361)
Lymphoma (322)
Machine learning (26)
Management (42)
Manufacturing (317)
MASH (44)
Medical device (1988)
Medtech (2000)
Mergers & acquisitions (2736)
Metabolic disorders (516)
Multiple sclerosis (103)
NASH (5)
Neurodegenerative disease (138)
Neuropsychiatric disorders (33)
Neuroscience (958)
Neurotech (1)
NextGen: Class of 2026 (1660)
Non-profit (1276)
Now hiring (16)
Obesity (202)
Opinion (237)
Ovarian cancer (109)
Pain (46)
Pancreatic cancer (90)
Parkinson's disease (87)
Partnered (17)
Patents (151)
Patient recruitment (203)
Peanut (11)
People (9619)
Pharmaceutical (11)
Pharmacy benefit managers (13)
Phase 1 (6841)
Phase 2 (7830)
Phase 3 (5801)
Pipeline (2140)
Policy (159)
Postmarket research (537)
Preclinical (2775)
Press Release (19)
Prostate cancer (116)
Psychedelics (26)
Radiopharmaceuticals (47)
Rare diseases (348)
Real estate (856)
Recruiting (58)
Regulatory (5238)
Reports (15)
Research institute (905)
Resumes & cover letters (445)
Rett syndrome (18)
RNA editing (8)
RSV (34)
Schizophrenia (51)
Series A (115)
Series B (86)
Service/supplier (1)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (35)
Sponsored (18)
Startups (815)
Stomach cancer (6)
Supply chain (49)
Tariffs (45)
The Weekly (30)
Vaccines (504)
Venture capital (58)
Weight loss (143)
Women's health (26)
Worklife (21)
Date
Today (6)
Last 7 days (249)
Last 30 days (839)
Last 365 days (13004)
2026 (1225)
2025 (13210)
2024 (10159)
2023 (8684)
2022 (10796)
2021 (12469)
2020 (11353)
2019 (9686)
2018 (7352)
2017 (6299)
2016 (5905)
2015 (6813)
2014 (4602)
2013 (3452)
2012 (3372)
2011 (3465)
2010 (2562)
Location
Africa (440)
Alabama (20)
Alaska (2)
Arizona (50)
Arkansas (5)
Asia (8107)
Australia (1751)
California (4747)
Canada (952)
China (501)
Colorado (130)
Connecticut (193)
Delaware (203)
Europe (20812)
Florida (425)
Georgia (95)
Hawaii (3)
Idaho (13)
Illinois (419)
India (17)
Indiana (125)
Iowa (16)
Japan (224)
Kansas (19)
Kentucky (7)
Louisiana (5)
Maine (8)
Maryland (503)
Massachusetts (3534)
Michigan (87)
Minnesota (188)
Mississippi (2)
Missouri (55)
Montana (1)
Nebraska (5)
Nevada (54)
New Hampshire (33)
New Jersey (1358)
New Mexico (11)
New York (1200)
North Carolina (417)
North Dakota (5)
Northern California (2314)
Ohio (115)
Oklahoma (4)
Oregon (15)
Pennsylvania (722)
Puerto Rico (4)
Rhode Island (17)
South America (446)
South Carolina (40)
Southern California (1731)
Tennessee (65)
Texas (745)
United States (15756)
Utah (59)
Virginia (103)
Washington D.C. (25)
Washington State (433)
West Virginia (2)
Wisconsin (91)
132,012 Results for "affini t therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Affini-T Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
·
1 min read
obesity
JPM26: Novartis Doesn’t Have a GLP-1. They Don’t Miss It In a World Of Me-Toos
Speaking to
BioSpace
at the J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal explains why the Swiss pharma hasn’t acquired a GLP-1, and why it probably won’t.
January 13, 2026
·
3 min read
·
Annalee Armstrong
Business
Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer
Affini-T Therapeutics, Inc. today announced the appointment of Kathy Bergsteinsson, MBA, as Chief Financial Officer.
November 13, 2023
·
3 min read
Genetown
Affini-T Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Affini-T Therapeutics, Inc. announced that Jak Knowles, M.D., Co-founder, President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 3:00 p.m. PT.
January 7, 2024
·
1 min read
Drug Development
Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Affini-T Therapeutics, Inc today announced that the first patient has been dosed in the Company’s Phase 1 clinical trial evaluating AFNT-211 targeting KRAS G12V. A Trial-In-Progress poster for this ongoing Phase 1 trial will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting held in Chicago, IL May 31-June 4.
May 28, 2024
·
3 min read
Genetown
Affini-T Therapeutics to Present Data From Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
Affini-T Therapeutics, Inc. today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11.
May 1, 2024
·
3 min read
Opinion
Automated Manufacturing Will Meet CAR T Demand
Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, global consistency and broader patient access to CAR T therapies.
January 6, 2026
·
3 min read
·
Ossama Eissa
Business
ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers
ElevateBio, LLC and Affini-T Therapeutics, today announced a partnership to advance Affini-T’s engineered TCR-T therapies focused on KRAS (Kirsten rat sarcoma viral oncogene homolog), one of the most prevalent oncogenic driver mutations in solid tumor cancers.
November 15, 2022
·
5 min read
Business
Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer
Affini-T Therapeutics, Inc. today announced the appointment of Thaminda Ramanayake as Chief Business Officer.
June 2, 2023
·
4 min read
Drug Development
Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024
Affini-T Therapeutics, Inc. announced that management is presenting data from the company’s oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H at this year’s American Association for Cancer Research Annual Meeting 2024 in San Diego.
April 7, 2024
·
4 min read
1 of 13,202
Next
